ALXN - Alexion Pharmaceuticals, Inc.
| Previous Close | 126.01 |
| Open | 126.48 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1000 |
| Day's Range | 126.12 - 129.29 |
| 52 Week Range | 92.56 - 141.86 |
| Volume | 1,245,585 |
| Avg. Volume | 1,483,324 |
| Market Cap | 28.926B |
| Beta (3Y Monthly) | 1.75 |
| PE Ratio (TTM) | 370.57 |
| EPS (TTM) | 0.35 |
| Earnings Date | Apr 24, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 163.00 |
- CNBC Videos•7 days ago
Technician lays out the best bets in biotech
Technician Chris Verrone looks at the best bets in biotech. With CNBC's Melissa Lee and the Fast Money traders, Pete Najarian, Tim Seymour, Steve Grasso and Guy Adami.
- Zacks•5 days ago
Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Investopedia•11 days ago
8 Stocks May Jump on Takeovers as Market Nears Peak
Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.
- Business Wire•11 days ago
Alexion to Report First Quarter Results on Thursday, April 25, 2019
Alexion Pharmaceuticals, Inc. today announced that the Company will report its financial results for the first quarter ended March 31, 2019 before the US financial markets open on April 25, 2019.
- Zacks•13 days ago
Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).
- Markit•14 days ago
See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding ALXN is favorable, with net inflows of $28.04 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Reuters•19 days ago
Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe
Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones. The U.S. Justice Department on Thursday said Jazz Pharmaceuticals Plc, Lundbeck and Alexion Pharmaceuticals Inc were the latest companies to settle claims stemming from an industry-wide probe of drugmakers' financial support of patient assistance charities. The government in an earlier settlement said drugmakers used such charities as a means to improperly pay the copay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.
- Reuters•19 days ago
Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe
Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones. The U.S. Justice Department on Thursday said Jazz Pharmaceuticals Plc, Lundbeck and Alexion Pharmaceuticals Inc were the latest companies to settle claims stemming from an industry-wide probe of drugmakers' financial support of patient assistance charities. The government in an earlier settlement said drugmakers used such charities as a means to improperly pay the copay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.
- American City Business Journals•19 days ago
Alexion, other drugmakers pay $123M to settle kickback claims
Prosecutors alleged that beginning in 2010, Alexion set up a fund to cover the out-of-pocket costs of its blockbuster drug Soliris.
- MarketWatch•19 days ago
Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations
The U.S. Justice Department said Thursday that Jazz Pharmaceuticals PLC , Alexion Pharmaceuticals Inc. and Lundbeck LLC have agreed to pay a combined $122.6 million to settle allegations that they paid kickbacks through co-pay assistance foundations for their own products. The companies violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program (ChampVA) copays for their own products, through purportedly independent foundations that the companies used as conduits, the Justice Department said in a statement. "The Anti-Kickback Statute prohibits a pharmaceutical company from offering or paying, directly or indirectly, any remuneration - which includes money or any other thing of value - to induce Medicare or ChampVA patients to purchase the company's drugs," said the statement. "This prohibition extends to the payment of patients' copay obligations." Jazz and Lundbeck have entered five-year corporate integrity agreements which require that they implement measures, controls and monitoring to promote independence from patient assistance programs. Alexion was exempted from that requirement because it has made sweeping changes following the bad conduct, said the statement. Changes included hiring a new eight-member executive leadership team and changing half of its board. Jazz shares were up 0.5% while Alexion shares were up 0.3%.
- Zacks•19 days ago
Achillion Meets Enrollment Target in Kidney Disease Studies
Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.
- Insider Monkey•25 days ago
Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy Right Now?
Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) an attractive stock to buy now? Money managers are betting on the stock. The number of bullish hedge fund bets increased by 4 recently. Our calculations also showed that ALXN isn't among the 30 most popular stocks among hedge funds. ALXN was in 41 hedge funds' portfolios at the end […]
- Zacks•26 days ago
Achillion Completes Enrollment in Rare Blood Disorder Study
Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.
- Zacks•27 days ago
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
Key highlights of the past week are multiple study failures and other pipeline updates.
- Motley Fool•last month
4 Blockbuster Drug Launches to Watch in 2019
These four experimental drugs will reach the market soon, and the companies launching them have little room for error.
- Market Realist•last month
Most Analysts Are Optimistic on Alexion Pharmaceuticals
How Major Rare Disease Pharma Stocks Are Positioned in MarchAnalysts’ recommendations and target priceWall Street analysts expect a potential upside of 21.63% for Alexion Pharmaceuticals (ALXN) based on the stock’s closing price on March 21.
- Investor's Business Daily•last month
IBD 50 Growth Stocks To Watch: After Climbing 403% From A 2009 Breakout, Can This Biotech Surge Again?
Earnings are rising again and revenue growth is accelerating at Alexion Pharmaceuticals, one of the current top growth stocks to watch in the IBD 50.
- Business Wire•last month
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
- Collaboration furthers Alexion’s complement leadership with expansion into peptide therapies -
- Business Wire•last month
Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
Alexion Pharmaceuticals, Inc. (ALXN) and Affibody AB today announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Currently in Phase 1 development, ABY-039 is a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn).
Motley Fool•last monthDicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript
DRNA earnings call for the period ending December 31, 2018.
- Simply Wall St.•last month
If You Had Bought Alexion Pharmaceuticals (NASDAQ:ALXN) Stock Five Years Ago, You’d Be Sitting On A 27% Loss, Today
While not a mind-blowing move, it is good to see that the Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) share price has gained 12% in the last three months. But that doesn't changeRead More...
